An LMU research team led by Professor Olivia M. Merkel, Chair of Drug Delivery at LMU, has developed a new delivery system ...
The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...
The field of cancer immunotherapy has achieved remarkable progress, introducing strategies such as immune checkpoint inhibitors and adoptive cell therapies ...
Tourmaline went public in 2023 via a reverse merger with the struggling cell therapy developer Talaris. The deal gave Tourmaline funds to develop pacibekitug, an antibody that targets interleukin-6, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results